| Literature DB >> 30669015 |
Zhiyuan Fan1, Junjie Deng2, Peter Y Li1, Daphney R Chery3, Yunfei Su4, Pu Zhu1, Taku Kambayashi5, Elizabeth P Blankenhorn6, Lin Han3, Hao Cheng7.
Abstract
Biological materials are superior to synthetic biomaterials in biocompatibility and active interactions with cells. Here, a new class of biological materials, cell membrane-derived hydrogel scaffolds are reported for harnessing these advantages. To form macroporous scaffolds, vesicles derived from red blood cell membranes (RBCMs) are chemically crosslinked via cryogelation. The RBCM scaffolds with a pore size of around 70 μm are soft and injectable. Highly biocompatible scaffolds are typically made of superhydrophilic polymers and lack the ability to encapsulate and release hydrophobic drugs in a controlled manner. However, hydrophobic molecules can be efficiently encapsulated inside RBCM scaffolds and be sustainedly released. RBCM scaffolds show low neutrophil infiltration after subcutaneous injection in mice, and a significantly higher number of infiltrated macrophages than methacrylate alginate (MA-alginate) scaffolds. According to gene expression and surface markers, these macrophages have an M2-like phenotype, which is anti-inflammatory and immune suppressive. There are also higher percentages of macrophages presenting immunosuppressive PD-L1 in RBCM-scaffolds than in MA-alginate scaffolds. Interestingly, the concentrations of anti-inflammatory cytokine, IL-10 in both types of scaffolds are higher than those in normal organ tissues. This study sheds light on cell membrane-derived hydrogels, which can actively modulate cells in unique ways unavailable to existing hydrogel scaffolds.Entities:
Keywords: Drug delivery; Immune modulation; Immunoengineering; Regenerative medicine; Tissue regeneration
Mesh:
Substances:
Year: 2019 PMID: 30669015 PMCID: PMC6369705 DOI: 10.1016/j.biomaterials.2019.01.020
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479